Anti-estrogen drugs such as tamoxifen have been used for treating patients with ER-positive, early breast cancer. However, resistance to anti-estrogen treatment is inevitable in most patients. Breast cancer anti-estrogen resistance-3 (BCAR3) has been identified as the protein responsible for the induction of tamoxifen resistance in estrogen-dependent human breast cancer. We have previously reported that BCAR3 regulates the cell cycle progression and the signaling pathway of EGF and insulin leading to DNA synthesis. In this study, we investigated the functional role of BCAR3 in regulating c-Jun transcription in non-tumorigenic human breast epithelial MCF-12A cells. A transient transfection of BCAR3 increased both the mRNA and protein of c-Jun expression, and stable expression of BCAR3 increased c-Jun protein expression. The overexpression of BCAR3 directly activated the promoter of c-jun, AP-1, and SRE but not that of NF-κB. Furthermore, single-cell microinjection of BCAR3 expression plasmid in the cell cycle-arrested MCF-12A cells induced c-Jun protein expression, and co-injection of dominant negative mutants of Ras, Rac, and Rho suppressed the transcriptional activity of c-Jun in the presence of BCAR3. Furthermore, stable expression of BCAR3 increased the proliferation of MCF-12A cells. The microinjection of inhibitory materials such as anti-BCAR3 antibody and siRNA BCAR3 inhibited EGF-induced c-Jun expression but did not affect IGF-1 induced upregulation of c-Jun. Taken together, we propose that BCAR3 plays a crucial role in c-Jun protein expression and cell proliferation and that small GTPases (e.g., Ras, Rac, and Rho) are required for the BCAR3-mediated activation of c-Jun expression.
Introduction
Over the past three decades, tamoxifen and other anti-estrogen drugs have been used for patients with estrogen receptor (ER)-positive, early breast cancer [7] . However, in metastatic breast cancer, more that 40% of patients eventually relapse and die from their disease. Several mechanisms underlying primary anti-estrogen resistance and progression of breast cancer have been proposed. Among them, new expression of genes including breast cancer anti-estrogen resistance (BCAR's) has been shown to induce resistance [24] . Among the six BCAR genes identified, BCAR3 has been of particular interest, as BCAR3 regulates cell proliferation, cell motility and invasion in breast cancer cells in the presence of anti-estrogen. Overexpression of BCAR3 in ER-positive human breast cancer cell lines (e.g., ZR-75-1 and MCF-7) results in a bypass of estrogen dependence for proliferation leading to anti-estrogen resistance [8, 15] . In addition, BCAR3 induces cell motility and migration of breast cancer cells [5, 15, 27] . We previously reported that microinjection of the BCAR3 gene into cell cycle-arrested human breast MCF-12A cells induces DNA synthesis comparable to oncogenic Ras gene [16] .
BCAR3 is a member of the Novel SH2-containing Protein (NSP) 1-3 family and their crystal structures show structural similarities, containing an N-terminal SH2 domain, a proline/serine-rich (P/S) domain and a C-terminal GEF domain [13] . The structural features of BCAR3 suggest that the BCAR3 may act as a signal transducer of growth factors.
We previously reported that BCAR3 directly interacts with tyrosine-phosphorylated EGF receptors through the SH2 domain of BCAR3 and regulates DNA synthesis induced by EGF and insulin [16, 17] . In addition, BCAR3 directly inter-acts with a downstream p130Cas, also known as BCAR1, through C-terminal GEF domain and acts as an adaptor molecule regulating cell transformation and cancer progression [26] . This BCAR3 association with receptors and signal transducers suggests an important functional role in the signaling pathway of growth factors. c-Jun is a component of the transcription factor activator protein-1 (AP-1) and regulates the expression of a wide array of genes involved in cell proliferation, cell differentiation, transformation, and cell death [14, 21] . It is well-known that c-Jun is overexpressed and associated with human breast cancers and with model cell and animal systems, and also plays a critical role in ras transformation and TPA-mediated carcinogenesis [1, 6, 11, 25, 29, 30] . Besides its oncogenic property, c-Jun is associated with anti-estrogen action in several ways. c-Jun mediates anti-estrogen-induced inhibition of breast cancer cell proliferation [28] . In addition, c-Jun overexpression followed by increased AP-1 activity produces anti-estrogen resistance in human breast cancer cells [11, 19, 22] . Therefore, it is important to understand a functional role of c-Jun in the development of anti-estrogen resistance.
Although the function of BCAR3 has been implicated in tamoxifen-resistant proliferation of breast cancer cells, its functional role in the proliferative process has been incompletely understood. In particular, the relationship between BCAR3 and c-Jun expression has not been studied.
In this study, we examined the functional roles of BCAR3 in c-Jun expression in normal breast MCF-12A cells. We propose that BCAR3 overexpression induces c-Jun expression through direct activation of its promoter and that BCAR3-mediated c-Jun induction is dependent on Ras, Rac and Rho. We also investigated the role of BCAR3 in the signal transduction pathways of EGF receptor associated with c-Jun protein expression. 
Materials and Methods

Materials
Cells culture
Immortalized normal human breast MCF-12A cells and MCF-7 cells were purchased from the ATCC (Mannassa, VA) and grown as suggested by the ATCC and maintained as described previously [16, 17] .
Plasmid Constructs, transfection, real-time PCR analysis
Myc-tagged BCAR3 expression vector was constructed by inserting the PCR product of BCAR3, Ras V12 , Ras N17 , Rac1 N17 and RhoA N19 into EcoRI/XhoI cloning sites of pCMV-Myc vector (Clontech, Mountain View, CA). Correct clones were selected using 100 μg/ml ampicillin. MCF-12A cells were transfected with control or BCAR3 containing myc plasmid with media including serum for 24 hr using DMRIE-C reagent (Invitrogen, Carlsbad, CA) as described previously [17] . To measure c-jun mRNA level, real-time fluorescence quantitative PCR was used as described previously [17] . The primer sequences used for real-time PCR were as follows: c-jun, forward, 5'-ggatcaaggcggaga-3'; reverse, 5'-gggcgattct ctccagctt-3'; β-actin, forward, 5'-ggacttcgagcaagagatgg-3'; reverse, 5'-agcactgtgt tggcgtacag-3'. PCR cycling conditions were 94°C for 3 min and 35 cycles (94°C for 5 s, 54°C for 30 s and 72°C for 20 s). Data were analyzed by a comparative cycle threshold method in Bio-Rad iQ5 software. In order to detect BCAR3 protein expression, transfected MCF-12A cells and MCF-7 cells were immunoblotted with BCAR3 antibody [16] .
Preparation of BCAR3-overexpressing cells and cell proliferation analysis
MCF-12A cells were transfected with either empty LNCX or BCAR3 expression LNCX vector [17] . Transfected cells were selected using G418 (100 μg/ml) and BCAR3 expression was verified by Western analysis. MCF-12A-LNCX and MCF-12A-BCAR3 cells were plated at a density of 5×10 4 cells in 35 mm plate. At indicated days, cells were collected by trypsinization, stained with trypan blue, and counted twice using a hemocytometer. For siRNA assay, MCF-12A and MCF-7 cells were plated at each density of 2.5×10 4 and 1×10 5 . After 24 hr, cells were transfected with control or BCAR3 siRNA for 24 hr, and then media change with complete media. After incubation for additional 24 hr, cells were harvested by trypsinization and counted.
Luciferase assays MCF-12A cells were grown on 12-well plate and transfected with the luciferase reporter containing c-jun, AP-1, SRE or NF-κB promoter construct (100 ng) using 3 μl of DMRIE-C reagent. The transfection mixture also included 50 μg of BCAR3, Ras V12 or pCMV-myc vector alone. After 24 hr of transfection, the cells were lysed with reporter lysis buffer and luciferase activities were determined using Luciferase Assay System (Promega, Madison, WI) according to the manufacturer's instructions.
Microinjection of antibodies, siRNA, and expression vectors
We previously reported single cell microinjection using a semiautomatic Eppendorf microinjection system [16, 17] .
Briefly, MCF-12A cells were grown on acid-washed coverslips for 24 hr and rendered quiescent by starvation for 24 hr in starvation medium. The following injection materials were diluted in PBS buffer for cytosolic injection or in nuclear injection buffer (50 mM HEPES, pH 7.2, 100 mM KCl, 50 mM NaPO4) for nuclear injection injection: 2 mg/ml of anti-BCAR3 antibody, anti-Ras antibody, 10 ng/ml of plasmid of Ras V12 , Ras N17 , Rac1 N17 , RhoA N19 and BCAR3, and 5uM siRNA of BCAR3. All microinjection materials contained rabbit IgG (3 mg/ml) for the detection of injected cells. Immunostaining and detection of c-Jun protein expression Following 1 hr stabilization after microinjection, the injected cells were stimulated with EGF (20 ng/ml) or IGF-1 (20 ng/ml) for 4 hr to detect c-Jun expression, respectively. c-Jun expression was examined as described previously [17] . The cells were fixed, permeabilized, and sequentially incubated with mouse anti-c-Jun antibody for 1 hr at 37°C followed by incubation with TRITC-conjugated anti-mouse IgG antibody for 30 min. To identify the injected cells were incubated with FITC-conjugated anti-rat IgG antibody for 30 min.
Statistical analysis
Results are obtained from three independent experiments.
Data are expressed as means ± standard error of the mean (SEM). The results were statistically analyzed by one-way ANOVA method. The results were analyzed by one-way ANOVA and the significance was examined with Fischer's Protected LSD post-hoc test. A P values <0.05 was considered statistically significant.
Results
Transfection and microinjection of BCAR3 promotes c-Jun protein expression
It has been demonstrated that c-Jun overexpression induces proliferation and invasiveness of breast cancer cells.
As such, we examined effects of BCAR3 on the expression Next, we investigated the downstream pathway of BCAR3 signaling on activation of c-jun promoter (Fig. 3B) . The BCAR3 expression plasmid with inhibitory materials was co-transfected into MCF-12A cells along with a reporter construct controlled by the c-jun promoter. BCAR3-induced activation of the c-jun promoter was inhibited by co-transfected dominant-negative mutants of H-Ras (Ras N17 ), Rac1 (Rac1 N17 ) and RhoA (RhoA N19 ). These results suggest that BCAR3mediated c-jun promoter activation requires small GTPases, such as Ras, Rac and Rho. The results described above demonstrated that BCAR3 over-expression significantly increased proliferation of MCF-12A cells. Therefore, we as- 
Discussion
BCAR3 overexpression has been known to increase proliferation and motility of breast cancer cell lines [8, 15, 20, 23 ]. However, the mechanism underlying BCAR3-mediated proliferation of breast cancer cells remains unclear. In this study, we report that BCAR3 plays a functional role in the proliferation of normal non-tumorigenic human breast MCF-12A cells. Stable expression of BCAR3 in MCF-12A cells increased proliferation, while depletion of BCAR3 by its siRNA decreased cell proliferation. Previously, we reported that microinjection of the BCAR3 gene into cell-cycle arrested MCF-12A cells induced cell cycle progression [16] .
Therefore, we conclude that BCAR3 regulates proliferation of normal and tumorigenic human breast cells. In order to understand the molecular mechanism of BCAR3-regulated cell proliferation, we examined whether BCAR3 regulates c-Jun transcription factors. We found that BCAR3 directly induced c-Jun protein expression in both transfected cells and microinjected cells. This induction of c-Jun was mediated through activation of c-Jun promoter. BCAR3 has been shown to activate the cyclin D1 promoter [4, 15] , and c-Jun transcription factor is known to regulate the expression of cyclin D1, a critical regulator of cell cycle progression. We also observed that BCAR3 induced cyclin D1 protein expression (data not shown). Therefore, c-Jun protein induction by BCAR3 may be important in increasing expression of cyclin D1, resulting in the proliferation of normal and cancer breast cells. Our results imply that BCAR3mediated induction of c-Jun expression and cyclin D1 expression could in part be responsible for tamoxifen resistance.
c-Jun also acts as a positive regulator of mitogenic responses to growth factors such as EGF and IGF-1 in cell cycle progression [1, 2, 11] . In this study, we report that c-Jun expression induced by growth factor requires BCAR3. When anti-BCAR3 antibody, BCAR3-SH2, or BCAR3 siRNA was introduced to MCF-12A cells by either single cell microinjection or transient transfection, the ability of EGF (but not IGF-1) to stimulate c-Jun expression was differentially abrogated. Previously, we reported that BCAR3 plays an important role in DNA synthesis stimulated by EGF, but not IGF-1 [16] . EGF and IGF-1 are important mitogenic growth factors in enhancing breast cancer cell proliferation as well as in inducing tamoxifen resistance [3, 10, 12, 18] . Taken together, these results are consistent with the hypothesis that BCAR3 is an important and necessary signaling molecule mediating the mitogenic effect of EGF, but not IGF-1.
In this study, we demonstrated that both BCAR3-mediat- 
